Institution
ACADIA Pharmaceuticals Inc.
Company•San Diego, California, United States•
About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.
Papers published on a yearly basis
Papers
More filters
Patent•
26 Nov 2013TL;DR: Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin are described in this paper, where the authors describe the use of the drug as an effective treatment for the disease.
Abstract: Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.
17 citations
TL;DR: Changing the balance between activation of NPFF receptor subtypes may provide one approach to reversing opiate tolerance, and in vitro experiments revealed that AC-263093 had equal affinity forNPFFR1 and NPFFR2, and functionally inactivated NPFF R1, in addition to its previously shown ability to activate NPFFr2.
17 citations
TL;DR: In this paper, a new series of 3-substituted pyrazolo[3,4-c]quinoline 1-oxides was synthesized using a regioselective bromine-magnesium exchange.
17 citations
Journal Article•
TL;DR: The clinical syndrome of psychosis in PD is described and data regarding the efficacy and tolerability of existing antipsychotic agents are described, and the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD is presented.
Abstract: Parkinson's disease (PD) is a movement disorder characterized by progressive degeneration of central dopaminergic systems. Current therapies designed to augment dopaminergic neurotransmission effectively treat the motoric aspects of the disease, however, with prolonged use, they produce a range of treatment-limiting side effects. Of these, neuropsychiatric abnormalities including hallucinosis and psychosis are common, disabling and refractory to most current therapies. This review describes the clinical syndrome of psychosis in PD and data regarding the efficacy and tolerability of existing antipsychotic agents, and presents the scientific rationale for the development of serotonin 2A receptor inverse agonists as potential therapeutic agents for treatment-induced psychosis of PD.
17 citations
TL;DR: Results indicate that the orphan peptide PHM-27 is a potent agonist at the hCTr, with similar efficacy as human calcitonin, and a potency of 11 nM.
17 citations
Authors
Showing all 261 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Michael Bachmann | 63 | 360 | 14388 |
| Daniel P. van Kammen | 47 | 168 | 6957 |
| Kristina Luthman | 39 | 158 | 7344 |
| Fredrik Almqvist | 37 | 170 | 4219 |
| Mark R. Brann | 35 | 77 | 5579 |
| Roger Olsson | 30 | 138 | 2752 |
| Uli Hacksell | 29 | 99 | 2954 |
| Torbjörn Frejd | 29 | 165 | 2889 |
| Petrine Wellendorph | 27 | 83 | 2573 |
| Ethan S. Burstein | 27 | 70 | 2255 |
| David M. Weiner | 26 | 45 | 3230 |
| Kimberly E. Vanover | 25 | 70 | 1955 |
| Uli Hacksell | 25 | 129 | 2879 |
| Magnus Gustafsson | 25 | 94 | 1546 |
| Mark R. Brann | 24 | 39 | 2576 |